JP2018500322A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500322A5 JP2018500322A5 JP2017532039A JP2017532039A JP2018500322A5 JP 2018500322 A5 JP2018500322 A5 JP 2018500322A5 JP 2017532039 A JP2017532039 A JP 2017532039A JP 2017532039 A JP2017532039 A JP 2017532039A JP 2018500322 A5 JP2018500322 A5 JP 2018500322A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogenic composition
- composition according
- years
- vzv
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 123
- 230000002163 immunogen Effects 0.000 claims description 68
- 229960005486 vaccine Drugs 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 33
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 101900123149 Varicella-zoster virus Envelope glycoprotein E Proteins 0.000 claims description 15
- 239000002502 liposome Substances 0.000 claims description 15
- 208000007514 Herpes zoster Diseases 0.000 claims description 14
- 229930182490 saponin Natural products 0.000 claims description 13
- 150000007949 saponins Chemical class 0.000 claims description 13
- 235000017709 saponins Nutrition 0.000 claims description 13
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 12
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 12
- 239000000556 agonist Substances 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- 239000002671 adjuvant Substances 0.000 claims description 11
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 9
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 9
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 9
- 238000002255 vaccination Methods 0.000 claims description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- 229930182558 Sterol Natural products 0.000 claims description 5
- 150000003432 sterols Chemical class 0.000 claims description 5
- 235000003702 sterols Nutrition 0.000 claims description 5
- 208000026278 immune system disease Diseases 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201422686 | 2014-12-18 | ||
| GB1422686.4 | 2014-12-18 | ||
| GB1503266.7 | 2015-02-26 | ||
| GB201503266A GB201503266D0 (en) | 2015-02-26 | 2015-02-26 | Vaccination |
| GB1518917.8 | 2015-10-26 | ||
| GBGB1518917.8A GB201518917D0 (en) | 2015-10-26 | 2015-10-26 | Vaccination |
| PCT/EP2015/079967 WO2016096968A1 (en) | 2014-12-18 | 2015-12-16 | Vaccination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018500322A JP2018500322A (ja) | 2018-01-11 |
| JP2018500322A5 true JP2018500322A5 (enExample) | 2018-12-27 |
Family
ID=54937057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532039A Pending JP2018500322A (ja) | 2014-12-18 | 2015-12-16 | ワクチン接種 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180008700A1 (enExample) |
| EP (1) | EP3233118A1 (enExample) |
| JP (1) | JP2018500322A (enExample) |
| CN (1) | CN107106675A (enExample) |
| BR (1) | BR112017012647A2 (enExample) |
| CA (1) | CA2970840A1 (enExample) |
| MX (1) | MX2017008055A (enExample) |
| WO (1) | WO2016096968A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11643441B1 (en) * | 2015-10-22 | 2023-05-09 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (VZV) |
| US20180327436A1 (en) | 2015-11-06 | 2018-11-15 | Adjuvance Technologies, Inc. | Triterpene saponin analogues |
| EP3615061A1 (en) * | 2017-04-28 | 2020-03-04 | GlaxoSmithKline Biologicals S.A. | Vaccination |
| MY195490A (en) * | 2018-05-23 | 2023-01-26 | Mogam Inst Biomedical Res | Antigen Variant Of Varicella Zoster Virus And Use Thereof |
| CN109602901B (zh) * | 2019-01-08 | 2022-05-27 | 成都迈科康生物科技有限公司 | 一种带状疱疹病毒疫苗及其制备方法和应用 |
| WO2020190750A1 (en) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Hiv rna vaccines |
| US20220409721A1 (en) * | 2019-11-05 | 2022-12-29 | Adjuvance Technologies, Inc. | Varicella zoster |
| US20250325656A1 (en) * | 2022-05-20 | 2025-10-23 | Glaxosmithkline Biologicals Sa | Modified varicella zoster virus glycoprotein e proteins |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0504436D0 (en) * | 2005-03-03 | 2005-04-06 | Glaxosmithkline Biolog Sa | Vaccine |
| TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
-
2015
- 2015-12-16 MX MX2017008055A patent/MX2017008055A/es unknown
- 2015-12-16 CN CN201580068948.3A patent/CN107106675A/zh active Pending
- 2015-12-16 US US15/535,723 patent/US20180008700A1/en not_active Abandoned
- 2015-12-16 EP EP15813347.0A patent/EP3233118A1/en not_active Withdrawn
- 2015-12-16 WO PCT/EP2015/079967 patent/WO2016096968A1/en not_active Ceased
- 2015-12-16 BR BR112017012647A patent/BR112017012647A2/pt not_active Application Discontinuation
- 2015-12-16 CA CA2970840A patent/CA2970840A1/en active Pending
- 2015-12-16 JP JP2017532039A patent/JP2018500322A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018500322A5 (enExample) | ||
| US20230116042A1 (en) | Adjuvant formulations comprising tlr4 agonists and methods of using the same | |
| EP2664332B1 (en) | Vaccine composition containing synthetic adjuvant | |
| Kamphuis et al. | Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats | |
| CN1391483A (zh) | 作为佐剂的聚氧乙烯脱水山梨醇酯和辛苯昔醇组合及其在疫苗中的应用 | |
| JP2003523310A (ja) | 新規インフルエンザウイルスワクチン組成物 | |
| HUP0203817A2 (hu) | Polioxietilén-alkil-étert vagy -észtert és legalább egy nemionos felületaktív anyagot tartalmazó adjuváns | |
| US11951161B2 (en) | Methods for inducing an immune response | |
| JP2018500322A (ja) | ワクチン接種 | |
| CN110621339A (zh) | 疫苗接种 | |
| JP2017511327A5 (enExample) | ||
| JP2017511324A5 (enExample) | ||
| Silveira et al. | Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice | |
| CA3157372A1 (en) | Varicella zoster | |
| WO2012042003A1 (en) | Improved vaccine compositions | |
| AR103030A1 (es) | Composición inmunógena | |
| EP2921178A1 (en) | Toll-like receptor 2 agonists and vaccines and uses thereof | |
| WO2016046113A1 (en) | Novel methods for inducing an immune response | |
| Acosta et al. | TB VACCINES BASED ON PROTEOLIPOSOMES AND LIPOSOMES FROM NON PATHOGENIC MYCOBACTERIA | |
| Lee | EFFECTS OF VACCINE PLATFORMS AND ADJUVANTS ON PROTECTIVE EFFICACY AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS | |
| HK1191545B (en) | Vaccine composition containing synthetic adjuvant |